Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. multidiag

MultiDiag

Rapid, cost-effective, multiplex point of care diagnostic immunoassay system

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 MultiDiag project word cloud

Explore the words cloud of the MultiDiag project. It provides you a very rough idea of what is the project "MultiDiag" about.

commercial    inherent    array    patient    infectious    biomarker    confirm    central    clinical    elisa    15    platform    changed    provides    reduce    care    bench    near    standard    healthcare    20min    cartridge    dramatically    multiplexed    complete    time    prepare    mainstay    diagnostic    retaining    accurate    sensitivity    takes    opportunity    first    contrast    assesses    point    rapid    disease    autoimmune    initial    manufacturable    diagnosis    accurately    perform    tests    size    lt    feasibility    facilities    submit    handling    followed    plan    benefits    data    our    tested    earliest    market    modern    laboratories    accuracy    pricing    disorders    mean    business    decades    hours    multiplex    laboratory    biomarkers    allergy    arrays    intend    made    quantitative    series    panels    incorporated    diagnoses    whilst    quantification    lined    commercialise    liquid    globally    device    cartridges    stream    oncology    nalia    competition    diseases    sensitive    disposable    parallel    immunoassays    route   

Project "MultiDiag" data sheet

The following table provides information about the project.

Coordinator		 NALIA SYSTEMS LIMITED 

Organization address
address: C/O DUBOFF & CO, KINGSBURY HOUSE, 468 CHURCH LANE
city: LONDON
postcode: NW9 8UA
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country United Kingdom [UK]
 Project website http://www.naliasystems.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2015
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-07-01   to  2015-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    NALIA SYSTEMS LIMITED UK (LONDON) coordinator 50˙000.00

Map

 Project objective

Our overall project is to develop and prepare to commercialise a rapid, cost-effective platform for near-patient diagnosis using multiplex immunoassays. Development of a cost-effective system for diagnosis by multiplex biomarker analysis at the point-of-care is essential to enable the delivery of modern, stream-lined healthcare systems in the EU and globally that rapidly and accurately assesses patient needs at the earliest opportunity. Immunoassays are a mainstay of clinical diagnoses. ELISA tests provide sensitive, accurate and quantitative diagnostic data for a large number of disease biomarkers. The technology has not changed for decades and requires central laboratory facilities. Each test measures only one biomarker and takes up to 2 hours to perform. NALIA Systems’ technology provides multiplexed ELISA tests in which panels of 10-15 biomarkers can be tested in parallel, whilst retaining the sensitivity, accuracy and quantification benefits of standard ELISA tests. The first NALIA Arrays are now being made available for use in laboratories. Standard ELISA technology cannot be adapted for use at point-of-care due to the time to result and the complex liquid handling needed. In contrast, the inherent characteristics of NALIA’s array technology mean that it can be incorporated into disposable cartridges and dramatically reduce the time to result. This project will develop a bench-top device and disposable cartridge system for biomarker arrays for diagnosis at the point of care. Initial arrays will be for autoimmune disorders, allergy and infectious diseases, followed by oncology and other diseases. In Phase 1 we intend to confirm the feasibility of achieving a result in <20min; to prepare a product development plan that will lead to a manufacturable device and series of cartridges; to complete a business plan covering all aspects of the commercial opportunity, pricing, market size, competition and route to market; and submit an application for Phase 2 funding.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MULTIDIAG" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MULTIDIAG" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination

Read More  

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More  

FAIR (2020)

FLAGELLIN AEROSOL THERAPY AS AN IMMUNOMODULATORY ADJUNCT TO THE ANTIBIOTIC TREATMENT OF DRUG-RESISTANT BACTERIAL PNEUMONIA

Read More